LGND
Ligand Pharmaceuticals
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: LGND
- PEG Ratio
As of Nov 13, 2026, LGND's PEG ratio of 7.93 reflects its valuation relative to its growth. This value reflects a P/E ratio of 116.52 measured against EPS growth of 14.7%. When compared to the trailing four-quarter average of 2.06, LGND's PEG ratio shows a 285% increase.
LGND PEG ratio history
Ligand Pharmaceuticals's ten years historical PEG ratio has a mean of 0.5. Compared to historical data, LGND's 7.93 PEG ratio represents an increase of 1,486%. LGND reached its maximum PEG ratio of 8.02 during the Sep 2026 quarter over the past ten years. The Mar 2019 quarter had the bottom reading at 0, indicating the most optimal growth-adjusted valuation.
Ligand Pharmaceuticals PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.01 | 29.36 | 3,027.3% |
| 2024 | N/A | N/A | -107.3% |
| 2023 | 0.09 | 23.65 | 252.5% |
| 2022 | N/A | N/A | -157.6% |
| 2021 | 0.02 | 44.9 | 2,011.1% |
| 2020 | N/A | N/A | -100.5% |
| 2019 | 0.01 | 3.15 | 389.4% |
| 2018 | 0.02 | 20.04 | 1,028.3% |
| 2017 | 0.27 | 228.22 | 850% |
| 2016 | N/A | N/A | -100.7% |
| 2015 | 0.01 | 9.34 | 1,867.8% |
| 2014 | 16.7 | 90.19 | 5.4% |
| 2013 | 0.05 | 93.93 | 1,966.7% |
| 2012 | N/A | N/A | -106.1% |
| 2011 | 0.13 | 24.22 | 192.5% |
Ligand Pharmaceuticals PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Sep 2026 | 8.02 | 117.88 | 14.7% |
| Jun 2026 | 0.09 | 31.39 | 347.4% |
| Mar 2026 | 0.12 | 25.27 | 209.7% |
| Dec 2025 | 0.01 | 29.36 | 3,027.3% |
| Sep 2025 | N/A | 76.68 | -12.5% |
| Jun 2025 | N/A | N/A | -266.8% |
| Mar 2025 | N/A | N/A | -232.1% |
| Dec 2024 | N/A | N/A | -107.3% |
| Sep 2024 | 0.22 | 37.91 | 175% |
| Jun 2024 | 0.62 | 34.53 | 55.4% |
| Mar 2024 | 0.05 | 13.41 | 292.1% |
| Dec 2023 | 0.09 | 23.65 | 252.5% |
| Sep 2023 | 0.36 | 62.42 | 175.6% |
| Jun 2023 | 0.11 | 45.92 | 434% |
| Mar 2023 | N/A | 52.92 | -2.1% |
LGND average PEG ratio chart
LGND's PEG ratio today sits above its 3, 5 and 10-year averages.
PEG comparison
With a PEG of 7.93, LGND stands above the Healthcare sector and the industry average.
LGND EPS growth
LGND Price vs fair value
LGND PEG vs peers
LGND has a PEG ratio above that of peer stocks LLY and AMGN.
Frequently asked questions
What is Ligand Pharmaceuticals's PEG ratio?
LGND's Nov 13, 2026 PEG ratio comes in at 7.93.
What is the 3-year average PEG ratio for Ligand Pharmaceuticals (LGND)?
LGND has a 3-year average PEG ratio of 1.15.
What is the 5-year average PEG ratio for Ligand Pharmaceuticals (LGND)?
LGND has a 5-year average PEG ratio of 0.88.
What is the highest PEG ratio for LGND?
In the last ten years, LGND's peak PEG ratio of 8.02 was recorded in the Sep 2026 quarter.
How does the current PEG ratio for LGND compare to its historical average?
Currently, LGND's PEG ratio is 1,486% higher than its 10-year historical average.
Why is Ligand Pharmaceuticals's PEG ratio so high?
A 7.93 PEG ratio for LGND suggests the stock is priced at a premium relative to its growth trajectory.
How is LGND's PEG ratio calculated (Ligand Pharmaceuticals PEG ratio formula)?
The PEG ratio comes from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Nov 13, 2026, Ligand Pharmaceuticals has a P/E ratio of 116.52. Earnings grew at 14.7% over the TTM period ending Sep 2026. Applying the formula, this gives a price to earnings growth ratio of 7.93. PEG RATIO(7.93) = PE RATIO(116.52) / EPS GROWTH(14.7%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.